Clinical Research Directory
Browse clinical research sites, groups, and studies.
3 clinical studies listed.
Filters:
Tundra lists 3 Low-Risk Prostate Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07924605
PSMA PET/MRI for Predicting and Detecting Prostate Cancer
The goal of this clinical trial is to see if a drug called 18F-DCFPyL can help find prostate cancer or prostate cancer that has spread to other parts of the body. The main question it aims to answer is: * Can 18F-DCFPyL predict response to therapy; and, * Does 18F-DCFPyL improve detection of early signs of cancer. Participants will undergo PET/MRI scans.
Gender: MALE
Ages: 18 Years - 85 Years
Updated: 2026-11-09
1 state
NCT07916779
Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle
Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and has been shown to control prostate cancer as well as longer treatment schedules. Large clinical studies have demonstrated excellent cancer control rates after SBRT. Although SBRT is effective, some men experience worsening erectile function after treatment. Researchers believe that reducing radiation exposure to the nerves and blood vessels involved in erections, known as the neurovascular bundles (NVBs), may help preserve sexual function. The EF-PRESERVE study is evaluating whether a specialized MRI-guided treatment approach can safely reduce radiation dose to these structures while still delivering effective treatment to the prostate cancer.
Gender: MALE
Ages: 18 Years - Any
Updated: 2026-11-04
NCT06866041
Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance
This study aims to identify patients with low-risk prostate cancer (ISUP Grade Group 1) eligible for active surveillance who are at higher risk of upgrading to ISUP Grade Group 2 or higher at confirmatory biopsy one year after diagnosis. Patients with low-risk ISUP GG1 tumors will be selected and undergo: * PSMA PET with calculation of SUVmax and PRIMARY-Likert score * Whole Exome Sequencing (WES) analysis on diagnostic prostate biopsies * Immunohistochemistry on diagnostic prostate biopsies * Confirmatory biopsy one year after diagnosis, as recommended by international guidelines This prospective, monocentric, single-arm interventional study will assess the predictive accuracy of a multivariable model integrating next-generation imaging and molecular biomarkers to improve risk stratification in active surveillance patients.
Gender: MALE
Ages: 45 Years - 80 Years
Updated: 2025-05-16
1 state